IP Library › Granted Patent US 11,091,481
Granted Patent B2
US 11,091,481 · App. 17/172,988 · Granted Aug 17, 2021

Heterocyclic compounds, preparation and methods and uses thereof

Inventor: Xing Dai (Short Hills, NJ)
Assignee: INVENTISBIO CO., LTD.
C07D471/04A61K31/282A61K31/438A61K31/519A61K33/243A61P35/00C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,091,481
App. No.
17/172,988
Granted
Aug 17, 2021
Kind
B2
Abstract

Provided herein are novel compounds, for example, compounds having a Formula (I) or Formula (II), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12C in a cell, and/or in treating various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (e.g., non-small cell lung cancer).

Claims (10)

1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is

2. A compound, which is

3. A pharmaceutical composition comprising the compound of claim 2 and a pharmaceutically acceptable excipient.

4. A method of treating cancer associated with KRAS G12C in a subject, the method comprising administering to the subject a therapeutically effective amount of the compound of claim 2 .

5. The method of claim 4 , wherein the cancer is a hematologic malignancy, lung cancer, pancreatic cancer, endometrial cancer, gall bladder cancer, thyroid cancer, bile duct cancer, and/or colorectal cancer.

6. A method of treating cancer associated with KRAS G12C in a subject, the method comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 2 .

7. The method of claim 6 , wherein the cancer is a hematologic malignancy, lung cancer, pancreatic cancer, endometrial cancer, gall bladder cancer, thyroid cancer, bile duct cancer, and/or colorectal cancer.

8. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

9. A method of treating cancer associated with KRAS G12C in a subject, the method comprising administering to the subject a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.

10. The method of claim 9 , wherein the cancer is a hematologic malignancy, lung cancer, pancreatic cancer, endometrial cancer, gall bladder cancer, thyroid cancer, bile duct cancer, and/or colorectal cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: DAI, XING; WANG, YAOLIN; JIANG, YUEHENG; LIU, YANQIN; SHI, ZHE; WANG, ZHENWU; TAO, LIANGSHAN; HAN, ZIXING; NIU, HAOTAO; WENG, JIFANG
To: INVENTISBIO CO., LTD.
Reel/Frame 055711/0353 →
Priority Claims (3)
WO PCT/CN2019/087772 · May 21, 2019 · international
WO PCT/CN2019/095947 · Jul 15, 2019 · international
WO PCT/CN2019/123223 · Dec 5, 2019 · international
Continuity (2)
Continuation PCTCN2020091274 · May 20, 2020
Related Publication 20210198255A1 · Jul 1, 2021
Cited By (3)
US 12,246,020 US 12,697,337 US 12,721,851